[go: up one dir, main page]

PE20091484A1 - PIRIDINONAS Y PIRIDAZINONAS QUE INHIBEN LA Btk - Google Patents

PIRIDINONAS Y PIRIDAZINONAS QUE INHIBEN LA Btk

Info

Publication number
PE20091484A1
PE20091484A1 PE2009000169A PE2009000169A PE20091484A1 PE 20091484 A1 PE20091484 A1 PE 20091484A1 PE 2009000169 A PE2009000169 A PE 2009000169A PE 2009000169 A PE2009000169 A PE 2009000169A PE 20091484 A1 PE20091484 A1 PE 20091484A1
Authority
PE
Peru
Prior art keywords
alkyl
pyridin
dihydro
halogen
amino
Prior art date
Application number
PE2009000169A
Other languages
English (en)
Inventor
Nolan James Dewdney
Joshua Kennedy-Smith
Bradley E Loe
Yan Lou
Joel Mcintosh
Timothy D Owens
Michael Soth
Zachary Kevin Sweeney
Joshua Paul Gergely Taygerly
Rama K Kondru
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20091484A1 publication Critical patent/PE20091484A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE PIRIDINONA Y PIRIDAZINONA DE FORMULAS (I), (II) Y (III), DONDE R ES H, R1, R1-R2-R3, ENTRE OTROS; R1 ES CICLOALQUILO C3-C7, HETEROCICLOALQUILO DE 3 A 8 MIEMBROS, ENTRE OTROS; R2 ES C(=O), C(=O)O, NHC(=O)O, ENTRE OTROS; R3 ES H O R4; R4 ES ALQUILO C1-C6, AMINO, ARILO, ENTRE OTROS; Y1 ES H, ALQUILO C1-C6 O HALOALQUILO C1-C10; X ES CH O N; n ES UN ENTERO DE 0 A 3; Y3 ES H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; m ES 0 O 1; Y4 ES Y4a, Y4b, Y4c O Y4d; Y4a ES H O HALOGENO; Y4b ES ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON OH, AMINO, ENTRE OTROS; Y4c ES CICLOALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C6, HALOGENO, OH, ENTRE OTROS; Y4d ES AMINO OPCIONALMENTE CON ALQUILO C1-C6, ALCOXI-ALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 6-DIMETILAMINO-2-(3-{1-METIL-5-[5-(MORFOLINA-4-CARBONIL)-PIRIDIN-2-ILAMINO]-6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL}-FENIL)-3,4-DIHIDRO-2H-ISOQUINOLIN-1-ONA, 7-TERT-BUTIL-3-(3-{1-METIL-5-[5-(MORFOLINA-4-CARBONIL)-PIRIDIN-2-ILAMINO]-6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL}-FENIL)-1H-QUINOLIN-4-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA TIROSINA QUINASA DE BRUTON (Btk) Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES E INFLAMATORIAS PROVOCADAS POR LA ACTIVACION DE LAS CELULAS B
PE2009000169A 2008-02-05 2009-02-04 PIRIDINONAS Y PIRIDAZINONAS QUE INHIBEN LA Btk PE20091484A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2620408P 2008-02-05 2008-02-05
US12251008P 2008-12-15 2008-12-15

Publications (1)

Publication Number Publication Date
PE20091484A1 true PE20091484A1 (es) 2009-10-03

Family

ID=40413736

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000169A PE20091484A1 (es) 2008-02-05 2009-02-04 PIRIDINONAS Y PIRIDAZINONAS QUE INHIBEN LA Btk

Country Status (29)

Country Link
EP (1) EP2242749B1 (es)
JP (1) JP5259739B2 (es)
KR (1) KR101308803B1 (es)
CN (1) CN101932573B (es)
AR (1) AR070408A1 (es)
AU (1) AU2009211514B2 (es)
BR (1) BRPI0907915A2 (es)
CA (1) CA2710462C (es)
CL (1) CL2009000229A1 (es)
CO (1) CO6290767A2 (es)
CR (1) CR11598A (es)
CY (1) CY1114114T1 (es)
DK (1) DK2242749T3 (es)
EC (1) ECSP10010384A (es)
ES (1) ES2420846T3 (es)
HR (1) HRP20130615T1 (es)
IL (1) IL206357A (es)
MA (1) MA32064B1 (es)
MX (1) MX2010008197A (es)
MY (1) MY158411A (es)
NZ (1) NZ586916A (es)
PE (1) PE20091484A1 (es)
PL (1) PL2242749T3 (es)
PT (1) PT2242749E (es)
RU (1) RU2505538C2 (es)
SI (1) SI2242749T1 (es)
TW (1) TWI382024B (es)
WO (1) WO2009098144A1 (es)
ZA (1) ZA201005539B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103327C2 (en) 2008-06-24 2013-10-10 Ф. Хоффманн-Ля Рош Аг Substituted pyridin-2-ones and pyridazin-3-ones
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2421854B1 (en) * 2009-04-24 2014-07-23 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
HUE043522T2 (hu) 2009-09-04 2019-08-28 Biogen Ma Inc Bruton tirozinkináz inhibitorok
SG185462A1 (en) * 2010-05-07 2012-12-28 Gilead Connecticut Inc Pyridone and aza-pyridone compounds and methods of use
EP2394998A1 (en) * 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
CN103582637B (zh) * 2011-05-17 2015-08-12 弗·哈夫曼-拉罗切有限公司 酪氨酸激酶抑制剂
AU2012296888A1 (en) 2011-08-17 2014-01-23 F. Hoffmann-La Roche Ag Inhibitors of Bruton's Tyrosine Kinase
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
CN104244939A (zh) 2012-04-05 2014-12-24 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
RU2015111133A (ru) * 2012-09-13 2016-11-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
JP6088063B2 (ja) * 2012-11-16 2017-03-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ブルトン型チロシンキナーゼの阻害剤
JP6042995B2 (ja) * 2012-11-30 2016-12-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ブルトン型チロシンキナーゼの阻害薬
CN105143215B (zh) * 2013-03-05 2017-12-08 豪夫迈·罗氏有限公司 布鲁顿氏酪氨酸激酶抑制剂
MX2015010820A (es) 2013-03-05 2015-11-30 Hoffmann La Roche Inhibidores de tirosina cinasa de bruton.
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
BR112015025260B1 (pt) 2013-04-25 2021-11-03 Beigene, Ltd Compostos heterocíclicos fundidos como inibidores da proteína quinase, sua composição, combinação e uso
CN104177338B (zh) * 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
CA2912359A1 (en) * 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone amide compounds
HRP20221262T1 (hr) 2013-09-13 2022-12-09 Beigene Switzerland Gmbh Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava
CA2929918C (en) * 2013-12-05 2018-01-23 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
EP3201186B1 (en) * 2014-10-02 2019-02-27 F. Hoffmann-La Roche AG Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk)
US10570118B2 (en) * 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
CA3019134C (en) 2016-03-31 2024-04-23 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
NZ749997A (en) 2016-07-05 2022-11-25 Beigene Ltd Combination of a pd-l antagonist and a raf inhibitor for treating cancer
EP3487852A1 (en) 2016-07-21 2019-05-29 Biogen MA Inc. Succinate forms and compositions of bruton's tyrosine kinase inhibitors
WO2018033853A2 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
TWI739887B (zh) 2016-08-19 2021-09-21 英屬開曼群島商百濟神州有限公司 使用包含btk抑制劑的組合產品治療癌症
AU2017326558B2 (en) 2016-09-19 2022-01-06 Mei Pharma, Inc. Combination therapy
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
CN106967073A (zh) * 2017-04-24 2017-07-21 刘双伟 一种治疗类风湿性关节炎的药物
CN108164536A (zh) * 2017-05-08 2018-06-15 刘双伟 一种用于治疗类风湿性关节炎的新的化合物的合成方法
TWI877099B (zh) 2017-06-26 2025-03-21 英屬開曼群島商百濟神州有限公司 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
WO2019034009A1 (en) 2017-08-12 2019-02-21 Beigene, Ltd. BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
EP3867242A1 (en) 2018-10-15 2021-08-25 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11464802B2 (en) 2019-04-09 2022-10-11 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
AU2020278592B2 (en) 2019-05-17 2024-10-10 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
TWI856111B (zh) 2019-06-10 2024-09-21 瑞士商百濟神州瑞士有限責任公司 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
CN114364670B (zh) 2019-06-26 2025-06-13 纽力克斯治疗公司 用于Cbl-b抑制的取代苄基-三唑类化合物及其进一步用途
WO2021091575A1 (en) * 2019-11-08 2021-05-14 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
EP4570320A3 (en) 2019-12-04 2025-08-27 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2022254104A1 (en) 2021-04-08 2023-10-26 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds
KR20240090898A (ko) 2021-10-26 2024-06-21 누릭스 테라퓨틱스 인코포레이티드 암을 치료 및 예방하고 btk를 분해하기 위한 피페리디닐피라진-카복스아미드 화합물
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3951395B2 (ja) * 1996-12-13 2007-08-01 田辺製薬株式会社 ピリジン誘導体、その製法及びその合成中間体
CZ20013289A3 (cs) * 1999-03-12 2002-01-16 Boehringer Ingelheim Pharmaceuticals, Inc. Sloučeniny výhodné jako protizánětové prostředky
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2006065946A1 (en) * 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
RU2396259C2 (ru) * 2004-12-24 2010-08-10 Астразенека Аб Амидные производные
CN101223141A (zh) * 2005-03-10 2008-07-16 Cgi药品股份有限公司 特定取代的酰胺,其制备方法和使用方法
WO2006124731A2 (en) * 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
CN101282975A (zh) * 2005-08-09 2008-10-08 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
ATE548363T1 (de) * 2005-08-29 2012-03-15 Vertex Pharma 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
BRPI0711628A2 (pt) * 2006-05-15 2011-12-06 Irm Llc composto, composição farmacêutica, uso e processo para preparação do composto

Also Published As

Publication number Publication date
PL2242749T3 (pl) 2013-09-30
CN101932573A (zh) 2010-12-29
RU2505538C2 (ru) 2014-01-27
ZA201005539B (en) 2011-04-28
EP2242749A1 (en) 2010-10-27
JP5259739B2 (ja) 2013-08-07
AU2009211514B2 (en) 2014-02-20
ECSP10010384A (es) 2010-09-30
IL206357A0 (en) 2010-12-30
SI2242749T1 (sl) 2013-07-31
CO6290767A2 (es) 2011-06-20
HRP20130615T1 (en) 2013-08-31
AR070408A1 (es) 2010-04-07
CA2710462C (en) 2015-11-24
PT2242749E (pt) 2013-07-16
CY1114114T1 (el) 2016-07-27
KR101308803B1 (ko) 2013-09-13
DK2242749T3 (da) 2013-06-17
TWI382024B (zh) 2013-01-11
KR20100093130A (ko) 2010-08-24
MX2010008197A (es) 2010-08-23
CN101932573B (zh) 2014-06-11
MA32064B1 (fr) 2011-02-01
MY158411A (en) 2016-10-14
CA2710462A1 (en) 2009-08-13
CL2009000229A1 (es) 2010-06-04
IL206357A (en) 2013-12-31
NZ586916A (en) 2012-06-29
ES2420846T3 (es) 2013-08-27
WO2009098144A1 (en) 2009-08-13
BRPI0907915A2 (pt) 2015-07-28
HK1146826A1 (en) 2011-07-15
TW200938538A (en) 2009-09-16
AU2009211514A1 (en) 2009-08-13
JP2011511027A (ja) 2011-04-07
RU2010136665A (ru) 2012-03-20
EP2242749B1 (en) 2013-04-10
CR11598A (es) 2010-10-27

Similar Documents

Publication Publication Date Title
PE20091484A1 (es) PIRIDINONAS Y PIRIDAZINONAS QUE INHIBEN LA Btk
PE20100851A1 (es) PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk
PE20110164A1 (es) Nuevas fenilpirazinonas como inhibidores de quinasa
PE20130774A1 (es) Compuestos heterociclicos activadores de ampk y metodos para emplearlos
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
PE20141120A1 (es) Compuestos heterociclicos
ECSP088253A (es) Derivados de azol y tiazol y sus usos
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
GT200600339A (es) Inhibidores macrociclicos del virus de la hepatitis c
MA32536B1 (fr) Composes organiques
CL2008000212A1 (es) Compuestos derivados de fenotiazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes, reducir los niveles de glucemia, adiccion a nicotina, adiccion al alcohol, trastornos del sistema nervioso central, entre
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
GT200700041A (es) Nuevos microbiocidas
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
NO20073105L (no) Pyridazinonforbindelser
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
DOP2006000178A (es) Derivados de isoquinolona sustituidos con piperidinilo
EA201170095A1 (ru) Производные (4-пиридин-4-ил)-1h-(1,3,5) триазин-2-она в качестве ингибирования gsk3-бета для лечения нейродегенеративных заболеваний
CO6210724A2 (es) Compuesto heterociclico y composicion farmaceutica del mismo
NO20085214L (no) Nye pyridinanaloger
CO6450684A2 (es) Derivado de amida
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
NO20081220L (no) Nytt cercosporamidderivat

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed